Development of a Bioadhesive Vaginal Gel for HIV Treatment
Author Information
Author(s): Chatterjee A, Bhowmik B, Thakur Y S
Primary Institution: Himalayan Pharmacy Institute, Majhitar, Rangpo, East Sikkim, India
Hypothesis
Can a new formulation of Zidovudine-loaded bioadhesive vaginal gel improve drug delivery and patient compliance for HIV treatment?
Conclusion
The F3 formulation of the bioadhesive vaginal gel showed improved drug release and bioavailability compared to the oral solution.
Supporting Evidence
- The F3 formulation showed a t90 of 24 hours for drug release.
- Bioavailability of the F3 formulation was found to be 123.89% compared to the oral standard.
- The study demonstrated good extrudability and spreadability of the gel.
- F3 formulation had a Cmax of 17.659 μg/mL in blood.
Takeaway
Researchers created a special gel that women can use to help prevent HIV, and it works better than taking a pill.
Methodology
The gel was prepared using a cold mechanical method and evaluated for drug release, bioadhesive strength, and pharmacokinetics in rabbits.
Potential Biases
Potential bias in the selection of formulations and animal models used for testing.
Limitations
The study was conducted on a small sample size of rabbits, which may not fully represent human responses.
Participant Demographics
Eight adult female rabbits (New Zealand white species) weighing 1.5–1.7 kg.
Statistical Information
P-Value
0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website